



ASX and Media Release

## **Conference Call on Results from Viralytics' Phase 1b MITCI Clinical Study in Advanced Melanoma**

### **CAVATAK® in Combination with YERVOY® - Latest Results**

---

**30 March 2017, Sydney, Australia:** [Viralytics Limited](#) (ASX: VLA, OTC: VRACY) is pleased to invite shareholders, investors and analysts to join a conference call on April 4 at 3pm US Eastern time (5am April 5 AEST) featuring Dr Brendan Curti MD, Director of the Biotherapy Program, Providence Cancer Center (Oregon, USA).

The call will address the clinical results from the ongoing Phase 1b MITCI<sup>1</sup> trial of the company's lead drug candidate, [CAVATAK®<sup>2</sup>](#), in combination with YERVOY®<sup>3</sup> (ipilimumab) including data from a podium presentation at the [American Association for Cancer Research \(AACR\) Annual Meeting 2017](#), held earlier in the day in Washington DC, USA.

Dr Curti will be available to take questions. He will be joined on the call by Viralytics CEO Dr Malcolm McColl and CSO Dr Darren Shafren. The call will last approximately 45 minutes in total.

### ***Conference Call Times:***

	<b><u>US Eastern Time</u></b>	<b><u>UK time</u></b>	<b><u>Australian Eastern Standard Time</u></b>
<b>Date:</b>	April 4 2017	April 4 2017	April 5 2017
<b>Time:</b>	3:00pm	8:00pm	5:00am

---

<sup>1</sup> MITCI (Melanoma Intra-Tumoral CAVATAK and Ipilimumab) study

<sup>2</sup> CAVATAK is a novel investigational cancer immunotherapy based on a proprietary cold virus that has been shown to preferentially infect and kill cancer cells and can boost the natural anticancer immune response.

<sup>3</sup> YERVOY® is a trademark of the Bristol-Myers Squibb Company.



Details for joining the call are as follows:

Country	Date	Time	Dial In
USA Pacific Mountain Central Eastern	April 4 2017	12 noon 1:00pm 2:00pm 3:00pm	Toll Free: 1866 519 4004
UK	April 4 2017	8:00pm	Toll Free: 0808 234 6646
Australia (AEST)	April 5 2017	5:00am	Toll Free: 1800 411 623
<b>Conference ID / Passcode (all locations):</b>			<b>94961440</b>

Please join the call at least 10 minutes before the start of the presentation.

The slide presentation and call can also be viewed via the following link:

<http://edge.media-server.com/m/p/rwfgnumf>

The presentation deck, entitled *"The MITCI (Phase 1b) study: A novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy treatment"* will be available at the time of the call from the Viralytics website at <http://www.viralytics.com/>.

The call and slide presentation will be recorded and a link provided on the Viralytics website.

#### **About Viralytics Ltd:**

Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. The company's lead investigational product, CAVATAK®, is currently being studied in Phase 1 and 2 clinical trials for the treatment of melanoma, as well as bladder and lung cancers. CAVATAK is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21) that preferentially binds to specific 'receptor' proteins highly expressed on multiple cancer types. CAVATAK acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells – a two-pronged mechanism of action known as oncolytic immunotherapy.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market. For more information, please visit [www.viralytics.com](http://www.viralytics.com).



**Enquiries:**

Dr Malcolm McColl  
Managing Director  
+61 2 9988 4000

Mr Robert Vickery  
Chief Financial Officer  
+61 2 9988 4000

Ms Jennifer Cook Williams  
Cook Williams Communications  
+1 360-668-3701  
[jennifer@cwcomm.org](mailto:jennifer@cwcomm.org)